Can-Fite BioPharma
AboutSciencePipielineInvestor InformationContact Us
About Can-Fite BioPharma About Can-Fite BioPharma About Can-Fite BioPharma About Can-Fite BioPharma About Can-Fite BioPharma

Can-Fite BioPharma (TASE: CFBI.TA) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancer diseases.

Science
The company technology platform is based on the finding that the Gi protein coupled A3 adenosine receptor (A3AR) is highly expressed in inflammatory and cancer cells whereas low expression is found in normal body cells. High A3AR expression levels are also >>  more...
Pipline
Can-Fite has a number of drugs in various stages of research and development. The pipeline drugs are synthetic, highly specific agonists and an allosteric modulator, all target the A3 adenosine receptor. All drugs are orally bioavailable with an excellent >> more...


News
February 22, 2012
FDA grants Orphan Drug Status for CF102 for the Treatment of Hepatocellular >> more...
February 22, 2012
OphthaliX announces issuance of Chinese Patent for the treatment of Dry >> more...

© Canfite 2012 | Disclaimer | Follow us on:    Homepage  |  Contact us  |  
only canfite.com